Form D · Biotechnology
PURPLE BIOTECH LTD.
Rehovot, L3 · CIK 0001614744
Offering snapshot reported Jul 15, 2024 · SEC filing
- Reported sold
- $4.51M Offering amount: $4.51M
- Investors reported
- 2 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jul 1, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jul 15, 2024 | Initial | $4,506,807 | No comparison | 2 | SEC filing |
| Oct 31, 2023 | Initial | $5,434,784 | No comparison | 1 | SEC filing |
| Jul 14, 2020 | Initial | $0 | No comparison | 1 | SEC filing |
| May 15, 2020 | Initial | $10,000,001 | No comparison | 3 | SEC filing |
| May 4, 2020 | Initial | $6,500,000 | No comparison | 3 | SEC filing |
| Jan 21, 2020 | Initial | $0 | No comparison | 2 | SEC filing |
| Jan 24, 2019 | Initial | $6,000,001 | No comparison | 2 | SEC filing |
| Jun 7, 2018 | Initial | $8,150,000 | No comparison | 4 | SEC filing |
| Mar 26, 2018 | Initial | $0 | No comparison | 2 | SEC filing |
| Nov 1, 2017 | Initial | $0 | No comparison | 1 | SEC filing |
| Aug 8, 2017 | Initial | $1,981,005 | No comparison | 14 | SEC filing |
| May 2, 2016 | Initial | $0 | No comparison | 1 | SEC filing |
| Feb 4, 2016 | Initial | $0 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $162K
- Finders' fees
- $0
- Form D file number
- 021-518799
This Form D is being filed in connection with the issuance of warrants to purchase up to an aggregate of 11,267,018 ADSs at an exercise price of $0.40 per ADS, with each ADS representing 10 ordinary shares, no par value per share, of the Company.
The placement agent (or its designees) also received warrants to purchase up to an aggregate of 394,346 ADSs at an exercise price of $0.45 per ADS, each representing 10 ordinary shares, no par value per share, of the Company.
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| H.C. Wainwright & Co., LLC | 000000375 |
Source: Form D, filed Jul 15, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Ido Agmon | Director |
| Gil Ben Menachem | Executive |
| Avraham Ben Tzvi | Executive |
| Gil Efron | Executive |
| Lior Fhima | Executive |
| Robert Gagnon | Director |
| Ori Hershkovitz | Director |
| Isaac Israel | Director |
| Yair Katzir | Director |
| Bertrand Liang | Executive |
| Yael Margolin | Director |
| Ido Morpurgo | Executive |
| Suzana Nahum Zilberberg | Director |
| Hadas Reuveni | Executive |
| Simcha Rock | Director |
| Eric Rowinsky | Director |
| Michael Schickler | Executive |
| Fabien Sebille | Executive |
| Philip Serlin | Director |
| Moran Sherf Blau | Director |
| Steven Steinberg | Director |
| Revital Stern Raff | Director |
| Ran Tzror | Director |
| John Paul Waymack | Director, Executive |
| Arye Weber | Director |
| Alain Zeitoun | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
4 Oppenheimer Street Science Park
Rehovot, L3, 7670104
Rehovot, L3, 7670104